Fairvalue-Calculator Fairvalue-Calculator
EN DE

Convatec Group (CNVVF) Fair Value & Analysis

Healthcare · US · Market cap $6.0B

Price$2.73
Fair Value$2.03
Upside-25.6%
Quality95/100
Evidence: High Range $1.18 – $2.86

Analysis

Convatec Group (CNVVF) currently trades at $2.73, while our model-based Fair Value estimate is $2.03 — implying the stock looks roughly 25.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such a…

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -60% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -16% Becton, Dickinson and Company (BDX) -26% Alcon Inc (ALC) -32%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.